Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations

Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations

<i>Background and Objectives</i>: Epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are effective first-line chemotherapeutic agents for patients with advanced non-small-cell lung cancer (NSCLC) harboring drug-sensitive <i>EGFR</i> mutations. However, th...

Full description

Bibliographic Details
Main Authors: Yutaka Yamada, Hisao Imai, Tomohide Sugiyama, Hiroyuki Minemura, Kenya Kanazawa, Takashi Kasai, Koichi Minato, Kyoichi Kaira, Takayuki Kaburagi
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Medicina
Subjects:
epidermal growth factor receptor
advanced non-small-cell lung cancer
elderly patients
re-administration
tyrosine kinase inhibitor
EGFR-TKI
Online Access:https://www.mdpi.com/1648-9144/57/9/929

Internet

https://www.mdpi.com/1648-9144/57/9/929

Similar Items